VIR | Vir Biotechnology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	10.01 - 10.58
52 Week Range	6.56 - 14.45
Beta	1.92
Implied Volatility	65.79%
IV Rank	20.08%
Day's Volume	1,384,979
Average Volume	2,188,195
Shares Outstanding	137,720,000
Market Cap	1,435,042,400
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-10-11

Valuation
Profitability
Growth
Health
P/E Ratio	-2.65
Forward P/E Ratio	N/A
EPS	-3.93
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	587
Country	USA
Website	VIR

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

VIR's peers: ABCL, ADPT, BLUE, IBRX, ONCY, SAVA, CVAC, RETA, KRYS, PPCB, ISEE, BPMC, AMLX, KRTX, DAWN, VKTX, ICPT, TERN, AKRO, PTCT, MDGL

*Chart delayed

Analyzing fundamentals for VIR we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see VIR Fundamentals page.

Watching at VIR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on VIR Technicals page.